964 / 1084
First line
Second line
Doublets or triplets?
What should be a standard?
03/28/2017
Molecular classification
Do we have distinct treatment choices for
these different molecular pathways?
How can we address tumor heterogenity
when we design GC clinical trials?
Are all patients candidated to a second line therapy?